View Item 

Show simple item record

A Novel Model Measuring the Harm of Transplanting Hepatocellular Carcinoma Exceeding Milan Criteria

dc.contributor.authorVolk, Michael L.en_US
dc.contributor.authorVijan, Sandeepen_US
dc.contributor.authorMarrero, Jorge A.en_US
dc.date.accessioned2010-06-01T22:08:16Z
dc.date.available2010-06-01T22:08:16Z
dc.date.issued2008-04en_US
dc.identifier.citationVolk, M. L.; Vijan, S.; Marrero, J. A. (2008). "A Novel Model Measuring the Harm of Transplanting Hepatocellular Carcinoma Exceeding Milan Criteria." American Journal of Transplantation 8(4): 839-846. <http://hdl.handle.net/2027.42/75159>en_US
dc.identifier.issn1600-6135en_US
dc.identifier.issn1600-6143en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/75159
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=18318783&dopt=citationen_US
dc.format.extent98429 bytes
dc.format.extent3109 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.publisherBlackwell Publishing Ltden_US
dc.rights2008 American Society of Transplantation and the American Society of Transplant Surgeonsen_US
dc.subject.otherEthicsen_US
dc.subject.otherHepatocellular Carcinomaen_US
dc.subject.otherLiver Transplantationen_US
dc.subject.otherPublic Policyen_US
dc.titleA Novel Model Measuring the Harm of Transplanting Hepatocellular Carcinoma Exceeding Milan Criteriaen_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelMedicine (General)en_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumDivision of Gastroenterology, University of Michigan Health System, 6312 Medical Science Building 1, 1150 W Medical Center Drive, Ann Arbor, MI 48109en_US
dc.contributor.affiliationumDivision of General Internal Medicine, University of Michigan, MIen_US
dc.contributor.affiliationotherVA Health Services Research and Development Center for Practice Management and Outcomes Research, VA Ann Arbor Healthcare System, Ann Arbor, MIen_US
dc.identifier.pmid18318783en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/75159/1/j.1600-6143.2007.02138.x.pdf
dc.identifier.doi10.1111/j.1600-6143.2007.02138.xen_US
dc.identifier.sourceAmerican Journal of Transplantationen_US
dc.identifier.citedreferencePenn I. Hepatic transplantation for primary and metastatic cancers of the liver. Surgery 1991; 110: 726 – 734; discussion 34–35.en_US
dc.identifier.citedreferenceMazzaferro V, Regalia E, Doci R et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: 693 – 699.en_US
dc.identifier.citedreferenceBarbara L, Benzi G, Gaiani S et al. Natural history of small untreated hepatocellular carcinoma in cirrhosis: A multivariate analysis of prognostic factors of tumor growth rate and patient survival. Hepatology 1992; 16: 132 – 137.en_US
dc.identifier.citedreferenceKulik L, Abecassis M. Living donor liver transplantation for hepatocellular carcinoma. Gastroenterology 2004; 127 ( 5 Suppl 1 ): S277 – S282.en_US
dc.identifier.citedreferenceBruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208 – 1236.en_US
dc.identifier.citedreferenceStuart KE, Anand AJ, Jenkins RL. Hepatocellular carcinoma in the United States. Prognostic features, treatment outcome, and survival. Cancer 1996; 77: 2217 – 2222.en_US
dc.identifier.citedreferenceLlovet JM, Real MI, Montana X et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: A randomised controlled trial. Lancet 2002; 359: 1734 – 1739.en_US
dc.identifier.citedreferenceEl-Serag HB, Davila JA, Petersen NJ, McGlynn KA. The continuing increase in the incidence of hepatocellular carcinoma in the United States: An update. Ann Intern Med 2003; 139: 817 – 823.en_US
dc.identifier.citedreferenceYao FY, Ferrell L, Bass NM, Bacchetti P, Ascher NL, Roberts JP. Liver transplantation for hepatocellular carcinoma: Comparison of the proposed UCSF criteria with the Milan criteria and the Pittsburgh modified TNM criteria. Liver Transpl 2002; 8: 765 – 774.en_US
dc.identifier.citedreferenceRoayaie S, Llovet JM. Liver transplantation for hepatocellular carcinoma: Is expansion of criteria justified ? Clin Liver Dis. 2005; 9: 315 – 328.en_US
dc.identifier.citedreferenceYao FY. Expanded criteria for hepatocellular carcinoma: Down-staging with a view to liver transplantation–yes. Semin Liv Dis 2006; 26: 239 – 247.en_US
dc.identifier.citedreferenceMerion RM, Schaubel DE, Dykstra DM, Freeman RB, Port FK, Wolfe RA. The survival benefit of liver transplantation. Am J Transplant 2005; 5: 307 – 313.en_US
dc.identifier.citedreference13.  UNOS. Policy 3.6, Organ Distribution: Allocation of Livers; revised September 18, 2007.en_US
dc.identifier.citedreferenceAmin MG, Wolf MP, TenBrook JA, Jr. et al. Expanded criteria donor grafts for deceased donor liver transplantation under the MELD system: A decision analysis. Liver Transpl 2004; 10: 1468 – 1475.en_US
dc.identifier.citedreferenceRoberts JP, Dykstra DM, Goodrich NP, Rush SH, Merion RM, Port FK. Geographic differences in event rates by model for end-stage liver disease score. Am J Transplant 2006; 6: 2470 – 2475.en_US
dc.identifier.citedreferenceRodriguez-Luna H, Vargas HE, Moss A, Reddy KS, Freeman RB, Mulligan D. Regional variations in peer reviewed liver allocation under the MELD system. Am J Transplant 2005; 5: 2244 – 2247.en_US
dc.identifier.citedreference17.  OPTN. 2005 Annual Report. 2005 [ cited December 18, 2006 ]; Available from: http://www.optn.org/data/annualReport.asp. Accessed January 15, 2007.en_US
dc.identifier.citedreferenceSarasin FP, Majno PE, Llovet JM, Bruix J, Mentha G, Hadengue A. Living donor liver transplantation for early hepatocellular carcinoma: A life-expectancy and cost-effectiveness perspective. Hepatology 2001; 33: 1073 – 1079.en_US
dc.identifier.citedreferenceCholongitas E, Marelli L, Shusang V et al. A systematic review of the performance of the model for end-stage liver disease (MELD) in the setting of liver transplantation. Liver Transpl 2006; 12: 1049 – 1061.en_US
dc.identifier.citedreferenceShechter SM, Bryce CL, Alagoz O et al. A clinically based discrete-event simulation of end-stage liver disease and the organ allocation process. Med Decis Making 2005; 25: 199 – 209.en_US
dc.identifier.citedreference21.  OPTN. 2006 Annual Report. Available from: http://www.optn.org/data/annualReport.asp.Accessed August 12, 2007.en_US
dc.identifier.citedreferenceLlovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. He patology 2003; 37: 429 – 442.en_US
dc.identifier.citedreferenceTakayasu K, Arii S, Ikai I et al. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology 2006; 131: 461 – 469.en_US
dc.identifier.citedreferencePelletier G, Ducreux M, Gay F et al. Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: A multicenter randomized trial. Groupe CHC. J Hepatol 1998; 29: 129 – 134.en_US
dc.identifier.citedreferenceOnaca N, Davis GL, Goldstein RM, Jennings LW, Klintmalm GB. Expanded criteria for liver transplantation in patients with hepatocellular carcinoma: A report from the International Registry of Hepatic Tumors in Liver Transplantation. Liver Transpl 2007; 13: 391 – 399.en_US
dc.identifier.citedreferenceBravata DM, Olkin I, Barnato AE, Keeffe EB, Owens DK. Health-related quality of life after liver transplantation: A meta-analysis. Liver Transpl Surg 1999; 5: 318 – 331.en_US
dc.identifier.citedreferenceLongworth L, Bryan S. An empirical comparison of EQ-5D and SF-6D in liver transplant patients. Health Econ 2003; 12: 1061 – 1067.en_US
dc.identifier.citedreferenceRatcliffe J, Longworth L, Young T, Bryan S, Burroughs A, Buxton M. Assessing health-related quality of life pre- and post-liver transplantation: A prospective multicenter study. Liver Transpl 2002; 8: 263 – 270.en_US
dc.identifier.citedreferenceBryce CL, Angus DC, Switala J, Roberts MS, Tsevat J. Health status versus utilities of patients with end-stage liver disease. Qual Life Res 2004; 13: 773 – 782.en_US
dc.identifier.citedreferenceRhodes R, Battin MP, Silvers A. Medicine and Social Justice: Essays on the Distribution of Health Care. Oxford: Oxford University Press; 2002.en_US
dc.identifier.citedreferenceUbel PA, Loewenstein G. Distributing scarce livers: The moral reasoning of the general public. Soc Sci Med 1996; 42: 1049 – 1055.en_US
dc.identifier.citedreferenceSmith CM, Davies DB, McBride MA. Liver transplantation in the United States: A report from the Organ Procurement and Transplantation Network. Clin Transpl 2007: 19 – 30.en_US
dc.identifier.citedreferenceStahl JE, Kong N, Shechter SM, Schaefer AJ, Roberts MS. A methodological framework for optimally reorganizing liver transplant regions. Med Decis Making 2005; 25: 35 – 46.en_US
dc.identifier.citedreferenceLlovet J, Ricci S, Mazzaferro V et al. Sorafenib improves survival in advanced Hepatocellular Carcinoma (HCC): Results of a Phase III randomized placebo-controlled trial (SHARP trial). J Clin Oncol 2007; 25 ( 18 Suppl 1 ): LBA1.en_US
dc.identifier.citedreferenceEl-Serag HB, Siegel AB, Davila JA et al. Treatment and outcomes of treating of hepatocellular carcinoma among Medicare recipients in the United States: A population-based study. J Hepatol 2006; 44: 158 – 166.en_US
dc.identifier.citedreferenceFreeman RB, Mithoefer A, Ruthazer R et al. Optimizing staging for hepatocellular carcinoma before liver transplantation: A retrospective analysis of the UNOS/OPTN database. Liver Transpl 2006; 12: 1504 – 1511.en_US
dc.identifier.citedreferenceMas VR, Fisher RA, Archer KJ et al. Genes associated with progression and recurrence of hepatocellular carcinoma in hepatitis C patients waiting and undergoing liver transplantation: Preliminary results. Transplantation 2007; 83: 973 – 981.en_US
dc.identifier.citedreferenceMashoi J, Puhl S, Thyagarajan V et al. Liver transplantation for hepatocellular carcinoma: Validation of the Milan criteria using the UNOS database. Hepatology 2006; 44 ( 4 Suppl 1 ): 407A.en_US
dc.identifier.citedreferenceDecaens T. What is the impact of UCSF expansion criteria according to pre-liver transplantation tumor characteristics on survival: Results from 14 French centers. Hepatology 2004; 40 ( 4 Suppl 1 ): 550A.en_US
dc.identifier.citedreferenceRoayaie S, Frischer JS, Emre SH et al. Long-term results with multimodal adjuvant therapy and liver transplantation for the treatment of hepatocellular carcinomas larger than 5 centimeters. Ann Surg 2002; 235: 533 – 539.en_US
dc.identifier.citedreferenceDuffy JP, Vardanian A, Benjamin E et al. Liver transplantation criteria for hepatocellular carcinoma should be expanded: A 22-year experience with 467 patients at UCLA. Ann Surg 2007; 246: 502 – 509; discussion 9–11.en_US
dc.identifier.citedreferenceYao FY, Ferrell L, Bass NM et al. Liver transplantation for hepatocellular carcinoma: Expansion of the tumor size limits does not adversely impact survival. Hepatology 2001; 33: 1394 – 1403.en_US
dc.identifier.citedreferenceYao FY. Liver transplantation for hepatocellular carcinoma: A 5-year prospective study validating expanded criteria applied to pre-operative imaging. Hepatology 2006; 44 ( 4 Suppl 1 ): 191A.en_US
dc.identifier.citedreferenceFreeman RB, Edwards EB, Harper AM. Waiting list removal rates among patients with chronic and malignant liver diseases. Am J Transplant 2006; 6: 1416 – 1421.en_US
dc.identifier.citedreferenceCheng SJ, Pratt DS, Freeman RB, Jr., Kaplan MM, Wong JB. Living-donor versus cadaveric liver transplantation for non-resectable small hepatocellular carcinoma and compensated cirrhosis: A decision analysis. Transplantation 2001; 72: 861 – 868.en_US
dc.identifier.citedreferenceSharma P, Balan V, Hernandez JL et al. Liver transplantation for hepatocellular carcinoma: The MELD impact. Liver Transpl 2004 Jan; 10: 36 – 41.en_US
dc.identifier.citedreferenceLlovet JM, Bustamante J, Castells A et al. Natural history of untreated nonsurgical hepatocellular carcinoma: Rationale for the design and evaluation of therapeutic trials. Hepatology 1999; 29: 62 – 67.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
j.1600-6143.2007.02138.x.pdf
Size:
96.12KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.